DENVER / Apr 26, 2023 / Business Wire / Modivcare Inc. (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today announced that Heath Sampson, Modivcare’s President and Chief Executive Officer, is scheduled to participate in a fireside chat presentation at the BofA Securities 2023 Health Care Conference in Las Vegas on Wednesday, May 10, 2023 at 3:00 p.m. (Pacific Daylight Time). Management will also host investor meetings throughout the day.
A link to the live webcast of the Company’s presentation can be found here or on Modivcare’s Investor Relations website at Modivcare Inc. - Investor Overview. A replay of the presentation will be available for 90 days following the date of the presentation.
About Modivcare
Modivcare Inc. (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their members. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal care and remote patient monitoring. To learn more about Modivcare, please visit www.modivcare.com.
Last Trade: | US$3.21 |
Daily Change: | -0.52 -13.94 |
Daily Volume: | 668,201 |
Market Cap: | US$46.060M |
May 05, 2025 April 25, 2025 April 23, 2025 March 06, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load